Clinical trial
GALLANT 14 Tesaglitazar vs. Metformin and Fenofibrate
NCT00261352 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT00261352 |
|---|---|
| Title | GALLANT 14 Tesaglitazar vs. Metformin and Fenofibrate |
| Official title | A 24-Week Randomised, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin or Metformin Combined With Fenofibrate) Study to Evaluate the Lipid Metabolic Effects, Safety and Tolerability of Tesaglitazar Therapy in Patients With Type 2 Diabetes and Low HDL-Cholesterol on a Fixed… |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes |
| Intervention type | Drug |
| Interventions | Tesaglitazar, Metformin, Fenofibrate |
| Enrollment | 1,000 |
| Start date | Mar 1, 2005 |
| Completion | Dec 1, 2006 |
| First posted | Dec 5, 2005 |
| Last update posted | Apr 22, 2009 |
| Countries | Brazil, Canada, Finland, France, Germany, Hong Kong, Hungary, India, Indonesia, Malaysia, Norway, Philippines and 6 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: